Published in Ther Adv Chronic Dis on May 01, 2010
EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLoS One (2013) 6.44
Effect of an electronic nicotine delivery device (e-Cigarette) on smoking reduction and cessation: a prospective 6-month pilot study. BMC Public Health (2011) 5.43
A fresh look at tobacco harm reduction: the case for the electronic cigarette. Harm Reduct J (2013) 1.93
Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study. Int J Environ Res Public Health (2013) 1.93
Successful smoking cessation with electronic cigarettes in smokers with a documented history of recurring relapses: a case series. J Med Case Rep (2011) 1.89
Metabolic effects of smoking cessation. Nat Rev Endocrinol (2016) 1.42
Electronic cigarettes and vaping: a new challenge in clinical medicine and public health. A literature review. Front Public Health (2013) 1.27
Success rates with nicotine personal vaporizers: a prospective 6-month pilot study of smokers not intending to quit. BMC Public Health (2014) 1.14
Knowledge and Perceptions about Nicotine, Nicotine Replacement Therapies and Electronic Cigarettes among Healthcare Professionals in Greece. Int J Environ Res Public Health (2016) 0.76
Putting tobacco harm reduction in perspective: is it a viable alternative? Indian J Med Res (2016) 0.75
The holistic perspective of chronic obstructive pulmonary disease: doubt some more. Ther Adv Chronic Dis (2010) 0.75
Lifestyle Vaccines and Public Health: Exploring Policy Options for a Vaccine to Stop Smoking. Public Health Ethics (2016) 0.75
Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ (2004) 24.88
Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction (2004) 9.12
Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev (2008) 8.69
Effect of an electronic nicotine delivery device (e cigarette) on desire to smoke and withdrawal, user preferences and nicotine delivery: randomised cross-over trial. Tob Control (2010) 7.97
Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem (2005) 6.13
Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA (2002) 5.63
Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA (2006) 5.19
Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev (2005) 4.86
A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry (2009) 4.66
Antidepressants for smoking cessation. Cochrane Database Syst Rev (2007) 4.62
Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation (2010) 4.50
Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Health Educational Authority. Thorax (1998) 4.43
Electronic nicotine delivery devices: ineffective nicotine delivery and craving suppression after acute administration. Tob Control (2010) 4.03
Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology (2006) 3.93
Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke. Circulation (1997) 3.74
Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev (2005) 3.15
Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin Pharmacol Ther (1988) 3.05
Physician advice for smoking cessation. Cochrane Database Syst Rev (2004) 2.84
The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med (1996) 2.32
Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med (1999) 2.31
Neurobiology of nicotine addiction: implications for smoking cessation treatment. Am J Med (2008) 2.29
Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther (2000) 2.26
Telephone counselling for smoking cessation. Cochrane Database Syst Rev (2003) 2.24
Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. Arch Intern Med (2009) 1.95
Cigarette smoking and diabetes. Prog Cardiovasc Dis (2003) 1.85
Clonidine for smoking cessation. Cochrane Database Syst Rev (2004) 1.80
SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol (2002) 1.75
Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther (1999) 1.67
Is nicotine replacement therapy for smoking cessation effective in the "real world"? Findings from a prospective multinational cohort study. Thorax (2007) 1.62
The clinical significance of "small" effects of smoking cessation treatments. Addiction (2007) 1.57
Pharmacotherapy for nicotine dependence. CA Cancer J Clin (2005) 1.54
Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology (2005) 1.51
Smoking cessation: progress, priorities, and prospectus. J Consult Clin Psychol (2002) 1.49
Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl) (2003) 1.49
A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychopharmacology (Berl) (2000) 1.42
Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J (2003) 1.35
A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry (1998) 1.33
Population effectiveness of pharmaceutical aids for smoking cessation: what is associated with increased success? Nicotine Tob Res (2006) 1.25
CB1 receptor antagonists for the treatment of nicotine addiction. Pharmacol Biochem Behav (2005) 1.20
Intensive smoking cessation counseling versus minimal counseling among hospitalized smokers treated with transdermal nicotine replacement: a randomized trial. Am J Med (2003) 1.19
Monoamine oxidase and tobacco dependence. Neurotoxicology (2006) 1.15
Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000. Eur J Clin Pharmacol (2003) 1.12
Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert Opin Investig Drugs (2007) 1.11
Nortriptyline for smoking cessation: a review. Nicotine Tob Res (2005) 1.02
A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry (2003) 1.02
A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction (2003) 0.99
Nicotine replacement therapy. What has been accomplished--can we do better? Drugs (1993) 0.96
Advances in pharmacotherapy for tobacco dependence. Expert Opin Emerg Drugs (2004) 0.96
Effects of selegiline (L-deprenyl) during smoking and short-term abstinence. Psychopharmacology (Berl) (2002) 0.96
Alpha2 adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev (2003) 0.95
Nicotine replacement: ten-week effects on tobacco withdrawal symptoms. Psychopharmacology (Berl) (1989) 0.94
Outcomes of bupropion therapy for smoking cessation during routine clinical use. Ann Pharmacother (2006) 0.91
Pharmacology of selegiline. Neurology (1996) 0.90
Clinical efficacy of bupropion in the management of smoking cessation. Drugs (2002) 0.89
A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers. Drug Alcohol Depend (2009) 0.89
Absolute bioavailability of nicotine applied to different nasal regions. Eur J Clin Pharmacol (1991) 0.85
Is clonidine an effective smoking cessation therapy? Drugs (1995) 0.84
No gender difference in effectiveness of smoking cessation treatment in a Brazilian real-life setting. Int J Tuberc Lung Dis (2006) 0.79
Real world study to evaluate the effectiveness of varenicline and cognitive-behavioural interventions for smoking cessation. Int J Environ Res Public Health (2009) 0.77
EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLoS One (2013) 6.44
Effect of an electronic nicotine delivery device (e-Cigarette) on smoking reduction and cessation: a prospective 6-month pilot study. BMC Public Health (2011) 5.43
Treatment strategies for allergy and asthma. Nat Rev Immunol (2008) 2.92
Estimating the harms of nicotine-containing products using the MCDA approach. Eur Addict Res (2014) 2.70
The emerging phenomenon of electronic cigarettes. Expert Rev Respir Med (2012) 2.46
The mechanisms, diagnosis, and management of severe asthma in adults. Lancet (2006) 2.40
Effectiveness and tolerability of electronic cigarette in real-life: a 24-month prospective observational study. Intern Emerg Med (2013) 2.03
A fresh look at tobacco harm reduction: the case for the electronic cigarette. Harm Reduct J (2013) 1.93
Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study. Int J Environ Res Public Health (2013) 1.93
Successful smoking cessation with electronic cigarettes in smokers with a documented history of recurring relapses: a case series. J Med Case Rep (2011) 1.89
TNF-alpha as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritis. Clin Sci (Lond) (2005) 1.66
A randomized, controlled study of specific immunotherapy in monosensitized subjects with seasonal rhinitis: effect on bronchial hyperresponsiveness, sputum inflammatory markers and development of asthma symptoms. Ann Ital Med Int (2004) 1.46
Obtaining good quality medical information from the World Wide Web. Ann Ital Med Int (2002) 1.39
Common predictors of smoking cessation in clinical practice. Respir Med (2008) 1.34
Adenosine in the airways: implications and applications. Eur J Pharmacol (2006) 1.29
Time for evidence-based e-cigarette regulation. Lancet Oncol (2013) 1.17
Diesel fumes and the rising prevalence of atopy: an urban legend? Curr Allergy Asthma Rep (2003) 1.14
Success rates with nicotine personal vaporizers: a prospective 6-month pilot study of smokers not intending to quit. BMC Public Health (2014) 1.14
The Health Effects of Electronic Cigarettes. N Engl J Med (2016) 1.08
Cigarette smoking is associated with a greater risk of incident asthma in allergic rhinitis. J Allergy Clin Immunol (2008) 1.06
Handling relapse in smoking cessation: strategies and recommendations. Intern Emerg Med (2012) 1.04
Cigarette smoke extract immobilizes human spermatozoa and induces sperm apoptosis. Reprod Biomed Online (2009) 0.99
Changes in airway hyperresponsiveness following smoking cessation: comparisons between Mch and AMP. Respir Med (2007) 0.97
Anti-TNF-alpha and Th1 cytokine-directed therapies for the treatment of asthma. Curr Opin Allergy Clin Immunol (2006) 0.95
Research applications and implications of adenosine in diseased airways. Trends Pharmacol Sci (2003) 0.94
Effect of treatment with nasal continuous positive airway pressure on ventilatory response to hypoxia and hypercapnia in patients with sleep apnea syndrome. Chest (2006) 0.94
Anti-IgE--emerging opportunities for Omalizumab. Expert Opin Biol Ther (2013) 0.92
Biologic and pharmacologic therapies in clinical development for the inflammatory response in COPD. Drug Discov Today (2010) 0.90
Therapeutic potential of adenosine receptor antagonists and agonists. Expert Opin Ther Pat (2007) 0.89
Electronic cigarette use and harm reversal: emerging evidence in the lung. BMC Med (2015) 0.89
Circulating endothelial-coagulative activation markers after smoking cessation: a 12-month observational study. Eur J Clin Invest (2010) 0.89
Greater severity of new onset asthma in allergic subjects who smoke: a 10-year longitudinal study. Respir Res (2011) 0.87
Preventing progression of allergic rhinitis to asthma. Curr Allergy Asthma Rep (2014) 0.87
The role of endogenous and exogenous AMP in asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol (2004) 0.86
Autologous fat grafting in the treatment of fibrotic perioral changes in patients with systemic sclerosis. Cell Transplant (2015) 0.85
Relevance of endothelial-haemostatic dysfunction in cigarette smoking. Curr Med Chem (2007) 0.84
Adenosine signaling pathways as potential therapeutic targets in respiratory disease. Expert Opin Ther Targets (2013) 0.84
Smoking cessation: present status and future perspectives. Curr Opin Pharmacol (2012) 0.82
Biologic therapy for atopic asthma and beyond. Curr Opin Allergy Clin Immunol (2013) 0.82
Adenosine signalling in airways. Curr Opin Pharmacol (2006) 0.82
Recurrent Hopkin's syndrome: a case report and review of the literature. J Neurol Sci (2010) 0.82
New and emerging infectious diseases. Allergy Asthma Proc (2007) 0.81
Nailfold videocapillaroscopy micro-haemorrhage and giant capillary counting as an accurate approach for a steady state definition of disease activity in systemic sclerosis. Arthritis Res Ther (2014) 0.81
Tobacco use cessation counseling of parents. Curr Opin Pediatr (2008) 0.81
Recommendation for optimal management of severe refractory asthma. J Asthma Allergy (2010) 0.81
Commentary on Dawkins et al. (2015): electronic cigarettes - from smoking cessation to smoking sensation and back. Addiction (2015) 0.81
Gas6 evaluation in patients with acute dyspnea due to suspected pulmonary embolism. Respir Med (2008) 0.80
Endothelial-coagulative activation during chronic obstructive pulmonary disease exacerbations. Haematologica (2008) 0.80
Off-label use of omalizumab in non-asthma conditions: new opportunities. Expert Rev Respir Med (2009) 0.80
Disabling inflammatory pathways with biologics and resulting clinical outcomes in severe asthma. Expert Opin Biol Ther (2013) 0.78
"Dangerous relationships": asthma and substance abuse. J Addict Dis (2013) 0.77
D-dimer in the diagnostic workup of suspected pulmonary embolism: additional clinical value of pretest probability. Chest (2005) 0.77
Heparin attenuates symptoms and mast cell degranulation induced by AMP nasal provocation. J Allergy Clin Immunol (2004) 0.77
Monoclonal antibodies for the treatment of severe asthma. Curr Allergy Asthma Rep (2011) 0.77
The role of adenosine as a novel bronchoprovocant in asthma. Curr Opin Allergy Clin Immunol (2003) 0.77
Adenosine receptors: promising targets for the development of novel therapeutics and diagnostics for asthma. Fundam Clin Pharmacol (2006) 0.76
Urban air pollution at the crossroads of the allergic pandemic. Ann Ital Med Int (2003) 0.76
Can immunotherapy prevent progression to asthma in allergic individuals? J Allergy Clin Immunol (2002) 0.76
Study of infliximab treatment in asthma. Am J Respir Crit Care Med (2007) 0.76
Caring for the smoking asthmatic patient. J Allergy Clin Immunol (2012) 0.76
Changes in sputum counts and airway hyperresponsiveness after budesonide: monitoring anti-inflammatory response on the basis of surrogate markers of airway inflammation. J Allergy Clin Immunol (2002) 0.76
The holistic perspective of chronic obstructive pulmonary disease: doubt some more. Ther Adv Chronic Dis (2010) 0.75
Poor quality of life in young smokers with smoking history of short duration. Chest (2005) 0.75
Rapid effect of inhaled fluticasone on airway responsiveness to AMP: research implications. J Allergy Clin Immunol (2003) 0.75
Exercise-induced asthma and plasma adenosine: Is there a causative link? J Allergy Clin Immunol (2002) 0.75
Study of infliximab treatment in smokers with COPD: what next? Am J Respir Crit Care Med (2005) 0.75
Tumor necrosis factor alpha in refractory asthma. N Engl J Med (2006) 0.75
Monitoring the adjustment of antiasthma medications with adenosine monophosphate bronchoprovocation. Chest (2004) 0.75
Commentary on Vangeli et al. (2011): Towards an improved understanding of smoking relapse predictors--recipe for success? Addiction (2011) 0.75
Mast cell degranulation after endobronchial adenosine challenge. J Allergy Clin Immunol (2005) 0.75
Smoking cessation and reduction in schizophrenia (SCARIS) with e-cigarette: study protocol for a randomized control trial. Trials (2014) 0.75
The puzzling relationship between cigarette smoking, reduced respiratory function, and systemic inflammation. Chest (2005) 0.75
Adenosine monophosphate challenge and monitoring of airway response to antiinflammatory therapy. Am J Respir Crit Care Med (2002) 0.75
Stratified medicine in selecting biologics for the treatment of severe asthma. Curr Opin Allergy Clin Immunol (2011) 0.75
[Malignant pleural mesothelioma in housewives in the province of Catania]. Recenti Prog Med (2004) 0.75
[Electronic cigarette: current overview and future perspectives]. Epidemiol Prev (2014) 0.75
Beclomethasone dipropionate attenuates airways hyperresponsiveness to neurokinin A and histamine in asthma. Respir Med (2005) 0.75